Cannabinoids are compounds associated with cannabis chemistry. Start with four names that often appear together on labels: THC, THCA, CBD and CBDA. Their relationships explain why an unheated sample and a heated product can have different chemical profiles.
- Start here
- Four linked cannabinoid references
- Focus
- Chemistry, labels and strength of evidence
Four compounds, two conversion pathways
These pathways describe chemistry, not a ranking of quality or a promise of benefit. An acidic precursor and its neutral counterpart are distinct compounds. Their measured amounts should stay separate until a clearly defined calculation is applied. [1]
THC
Understand intoxication, concentration versus dose, and how THC relates to THCA.
THCA
Understand heating, potential THC and why a low delta-9 number is incomplete.
CBD
Separate CBD evidence and product labels from assumptions about safety.
CBDA
Understand CBD’s acid precursor and the limits of emerging human research.
How to compare cannabinoid information
- Identify the exact compound, not just the product’s headline ingredient.
- Check whether a figure is measured, calculated, or a general directory range.
- Match units and reporting basis before comparing numbers.
- Separate evidence about an isolated compound from evidence about a mixture.
- Read uncertainty as useful information, rather than a gap to fill with a confident claim.
A strain profile and a batch report answer different questions
A named strain helps organize reported genetics and traits. A certificate of analysis describes an identified sample tested with a particular method. A familiar name or a photograph cannot replace that sample record. Begin with the strain directory, then use the THC and CBD reading guide to interpret the figures you encounter.
How this reference handles evidence
Each profile identifies the kinds of evidence behind its main distinctions. The pages do not treat preclinical findings as established treatment benefits or assign invented confidence percentages. Human evidence for acidic cannabinoids remains limited, and mixed-product findings cannot identify every ingredient’s contribution. [2] [3]
This first collection covers four cannabinoids. It is not an exhaustive chemical inventory, a product recommendation or a jurisdiction-specific legal guide. We consolidate overlapping questions on the relevant profile instead of publishing a separate page for each wording.
Need a definition while reading a report? Use the cannabis glossary for terms such as cannabinoid, batch and certificate of analysis.
Hemp Lookup editorial reference. Evidence checked November 11, 2026. No independent clinical review is claimed. This page explains compounds and labels; it does not prescribe treatment or determine a product’s legal status.
Evidence and sources
- Wang et al., 2016 — experimental decarboxylation study
Analytical laboratory study; supports conversion chemistry, not treatment effects.
- Therapeutic potential of acidic cannabinoids: an update, 2026
Narrative review; highlights preclinical findings and the shortage of controlled human trials.
- Elder et al., 2025 — human study of a mixed cannabinoid extract
Human laboratory study of a mixture containing CBD, CBDA, THC and THCA; cannot isolate the contribution of CBDA or THCA.